Group 1 - The company, HaiXi Pharmaceutical (02637.HK), plans to globally offer 11.5 million shares, with 1.15 million shares available in Hong Kong and 10.35 million shares for international sale [1] - The subscription period is from October 9 to October 14, with a maximum offer price of HKD 86.40 per share, and the entry fee is approximately HKD 4,363.57 for a trading unit of 50 shares [1] - The total expected fundraising amount is HKD 899 million, with a net amount of HKD 848 million, which will be used for ongoing R&D investments, enhancing R&D capabilities, seeking collaboration opportunities, and improving commercialization and production systems [1] Group 2 - The company has introduced cornerstone investors, including Harvest Oriental SP, who will subscribe to approximately 198,170 shares at the offer price [1] - The company is expected to be listed on the main board on October 17, 2025, with Huatai Financial Holdings (Hong Kong) and China Merchants Jinling International as joint sponsors [1] - The company is a commercial-stage pharmaceutical firm with integrated R&D, production, and sales capabilities, possessing a diverse product portfolio and pipeline in China's largest and fastest-growing therapeutic areas [1] Group 3 - The company's net profits for the fiscal years ending December 31 are projected to be CNY 68.981 million for 2022, CNY 117 million for 2023, and CNY 136 million for 2024 [2]

截至2025年中报，歌礼制药-B营业总收入108.1万元、净利润-8795.1万元。 本文源自：金融界 作者：行情君 8月19日，歌礼制药-B(01672)盘中下跌9.64%，截至09:30，报16.5元/股，成交8.83亿元。 歌礼制药有限公司是一家创新研发驱动型生物科技公司，主要从事病毒性疾病、非酒精性脂肪性肝炎和 肿瘤等三大医疗领域的新药研发、生产和商业化。该公司在浙江绍兴滨海新城拥有约17,000平方米的生 产基地，设计年产能为1.3亿片，拥有多款在研药物并已取得药品生产许可证。 ...

Group 1 - The company is focusing on a dual-driven development strategy of "technology & market" [2] - The company has 34 independent research and development projects, with 20 projects currently in clinical trials or registration application stages [2] - Investors are inquiring about the company's potential development of a cure for AIDS [2]